MARY-KAY
2.11.2021 18:48:11 CET | Business Wire | Press release
Mary Kay Inc. is proud to announce the sponsorship of a project to improve water security in Monterrey in partnership with The Nature Conservancy. The project, led by a group of female entrepreneurs, focuses on restoring local species of trees in the surrounding areas of the city of Monterrey to help maintain ecosystem services, decrease the risk and impact of floods in the city, and restore the degraded forests in the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211102006106/en/
The City of Monterrey is currently home to four million people. Located in an area naturally prone to extreme hydrometeorological events such as hurricanes and flooding, the city often faces serious water supply challenges. Near the city is the Cumbres de Monterrey National Park, a protected natural reserve that accounts for about 60% of the water that comes to the city. The area also supports the control of heavy stormwater runoff which impacts people, local livestock, and urban infrastructure. To maintain environmental resiliency, vegetation cover needs to be restored and the production of native plants in nurseries must be ensured. While the National Commission of Protected Natural Areas of Mexico (CONANP) has established regulations requiring the use of native species for reforestation, forest nurseries in the region do not have the capacity to meet this demand. The area also offers very few opportunities for local farmers to develop self-sustaining economic activities.
“We are very happy to be able to count on this help that encourages us to continue working for the benefit of nature and to be able to generate resources that improve our local economy,” said Doña Angelica, leader of Mujeres Unidas Para La Conservación de Laguna de Sanchez, one of The Nature Conservancy’s partner organizations in Mexico. “With this help we will be able to reduce the production costs of plants that will be used in future reforestations.”
Mary Kay and The Nature Conservancy are supporting a group of female entrepreneurs in the Laguna Sanchez community who are leading a unique initiative to combat these challenges. This group of landowners is producing several native species of plants to be used for reforestation projects in the national park. The project will not only address the rising need for these species, but also improve livelihoods for their families and rural community members. Their forest nursery has the capacity to grow around 45,000 trees per year, including white pine (Pinus pseudostrobus ) and stone pine (Pinus cembroides ). These species, included in a scientific tool developed by The Nature Conservancy for ecological restoration in the area, are known for preventing erosion, promoting water infiltration, drought tolerance, and have the ability to regrow.
“Empowering women and preserving the Earth’s resources are two of the pillars of Mary Kay’s purpose,” said Deborah Gibbins, Chief Operating Officer at Mary Kay Inc. “As an advocate for women’s leadership, we are very proud to see how these local leaders are steering the change in our community, playing a critical role in the preservation of our most valuable natural resource and nurturing a sustainable future for thousands of families in the region.”
To help tell the story of empowerment and natural conservation of Angelica and Mujeres Unidas Para La Conservación de Laguna de Sanchez , Mary Kay Inc. has produced a short film in partnership with The Nature Conservancy. Written, directed and produced by an all-female team, Forest of Hope is a journey to the frontlines of the battle to save our planet from the impending threats of climate change and destructive human behavior, where we see the difference a group of women conservationists can make. Watch the trailer of Forest of Hope here .
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more about Mary Kay at www.marykayglobal.com
About The Nature Conservancy
The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world's toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters and oceans at an unprecedented scale, providing food and water sustainably and helping make cities more sustainable. Working in 79 countries and territories, we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102006106/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
